Holen Sie sich die Stockscreener-App
8.54
0.12%
-0.01
Schlusskurs vom Vortag:
$8.55
Offen:
$8.55
24-Stunden-Volumen:
755.34K
Relative Volume:
0.20
Marktkapitalisierung:
$354.50M
Einnahmen:
$324.00K
Nettoeinkommen (Verlust:
$-82.10M
KGV:
-9.1828
EPS:
-0.93
Netto-Cashflow:
$-69.18M
1W Leistung:
+0.00%
1M Leistung:
-0.12%
6M Leistung:
+893.14%
1J Leistung:
+780.59%
1-Tages-Spanne:
$8.54
$8.55
1-Wochen-Bereich:
$8.54
$8.55
52-Wochen-Spanne:
$0.75
$8.55
Chimerix Inc Stock (CMRX) Company Profile
Firmenname
Chimerix Inc
Sektor
Branche
Telefon
919.806.1074
Adresse
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Vergleichen Sie CMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.54 | 354.50M | 324.00K | -82.10M | -69.18M | -0.93 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2021-04-29 | Eingeleitet | Maxim Group | Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-31 | Eingeleitet | Jefferies | Buy |
| 2021-03-31 | Eingeleitet | Wedbush | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-02-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-09 | Bestätigt | FBR Capital | Mkt Perform |
| 2016-02-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2016-02-23 | Bestätigt | FBR Capital | Mkt Perform |
| 2016-02-23 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2015-12-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-28 | Herabstufung | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | Bestätigt | Piper Jaffray | Overweight |
| 2015-12-17 | Eingeleitet | UBS | Buy |
| 2015-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | Eingeleitet | Citigroup | Buy |
| 2015-08-18 | Eingeleitet | FBR Capital | Outperform |
| 2015-08-06 | Bestätigt | Brean Capital | Buy |
| 2015-05-11 | Bestätigt | Brean Capital | Buy |
| 2015-03-04 | Eingeleitet | Barclays | Overweight |
| 2015-02-12 | Bestätigt | Stifel | Buy |
| 2014-12-31 | Bestätigt | Brean Capital | Buy |
| 2014-07-08 | Fortgesetzt | Brean Capital | Buy |
Alle ansehen
Chimerix Inc Aktie (CMRX) Neueste Nachrichten
StockNews.com Initiates Coverage on Chimerix (NASDAQ:CMRX) - Defense World
Halper Sadeh LLP, bluebird bio, Inc., Walgreens Boots Alliance, Chimerix, Inc. - Olean Times Herald
Chimerix (NASDAQ:CMRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
Why Chimerix Inc. (CMRX) is Surging in 2025 - Insider Monkey
Investor Network: Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
Geode Capital Management LLC Lowers Stock Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa
Chimerix Terminates Loan and Delists from Nasdaq - TipRanks
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ St - GuruFocus
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ Stock News - GuruFocus
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com - Defense World
Chimerix stock soars to 52-week high, hits $8.54 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.54 - Investing.com
Unlocking Investment Potential Discover the Power of Magical Signals Bullish Signal - AInvest
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025? - MSN
Jazz Pharmaceuticals, Chimerix HSR waiting period expired on March 31 - MLex
11 Best Performing NASDAQ Stocks So Far in 2025 - Insider Monkey
Exploring US High Growth Tech Stocks In March 2025 - simplywall.st
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 - Yahoo
11 Best Performing Stocks So Far In 2025 - Insider Monkey
Jazz strikes the chord with $935m Chimerix acquisition - BioXconomy
Chimerix Reports 2024 Losses Amid Acquisition News - TipRanks
Chimerix earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Chimerix Inc Reports Q4 2024 EPS of -$0.25, Beating Estimates; R - GuruFocus.com
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued - Endpoints News
Chimerix: Q4 Earnings Snapshot - mySA
Chimerix Inc. (CMRX) reports earnings - Quartz
CHIMERIX INC SEC 10-K Report - TradingView
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Finanzdaten der Chimerix Inc-Aktie (CMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):